Analyst Ratings for Revolution Medicines
Portfolio Pulse from Benzinga Insights
Revolution Medicines (NASDAQ:RVMD) has received positive analyst ratings in the last quarter, with 3 bullish and 1 somewhat bullish ratings. The average 12-month price target for the company is $35.25, which has increased by 4.69% over the past month.
August 09, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Revolution Medicines has received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up in the short term.
Analyst ratings are a significant factor that investors consider when making investment decisions. The positive ratings for Revolution Medicines indicate a positive outlook for the company, which could lead to increased investor interest and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100